Fixed-dose combination
Doxecitine and Doxribtimine is a fixed-dose combination medicine indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. MedsAcross supplies Doxecitine and Doxribtimine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
Source: US FDA prescribing information
Administration of KYGEVVI is intended to incorporate the pyrimidine nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.
Source: US FDA prescribing information
Obtain baseline transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) levels in all patients prior to treatment initiation. Recommended dosage: KYGEVVI Dosage Level KYGEVVI Dosage (mg/kg/day) Starting 260 mg/kg/day (consisting of 130 mg doxecitine and 130 mg doxribtimine) Intermediate 520 mg/kg/day (consisting of 260 mg doxecitine and 260 mg doxribtimine) Maintenance 800 mg/kg/day (consisting of 400 mg doxecitine and 400 mg doxribtimine) Titrate to the next dosage level based on tolerability after a minimum of 2 weeks at the current dosage level. Administer KYGEVVI orally in 3 equally divided doses with food. See full prescribing information for dosage and administration modifications, monitoring, and preparation and administration instructions. Use KYGEVVI only with ZX2000 administration kit.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Elevated Liver Transaminase Levels: Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels prior to treatment initiation with KYGEVVI. If signs or symptoms consistent with liver injury are observed, interrupt treatment. Consider permanently discontinuing KYGEVVI if signs/symptoms consistent with liver injury persist or worsen. Monitor patients yearly and as clinically indicated. Gastrointestinal Adverse Reactions: Reduce KYGEVVI dosage or interrupt treatment based on severity of diarrhea and/or vomiting. If persistent severe diarrhea and/or vomiting occurs, consider discontinuing KYGEVVI permanently.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Elevated Liver Transaminase Levels Gastrointestinal Adverse Reactions Most common adverse reactions (incidence ≥5%) are diarrhea, abdominal pain (including abdominal pain upper), vomiting, alanine aminotransferase increased (ALT), and aspartate aminotransferase increased (AST).
Source: US FDA prescribing information
Store KYGEVVI packets at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C (59°F to 86°F). Store reconstituted KYGEVVI solution at controlled room temperature or in the refrigerator.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Doxecitine and Doxribtimine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Kygevvi 2 g/2 g powder for oral solutionOral | Doxecitine and Doxribtimine | UCB | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Doxecitine and Doxribtimine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Doxecitine and Doxribtimine, including Kygevvi.
Yes. The US FDA first approved Doxecitine and Doxribtimine on 3 November 2025, according to Drugs@FDA.
Yes. Doxecitine and Doxribtimine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Doxecitine and Doxribtimine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Doxecitine and Doxribtimine is classified under ATC code A16AX29 (Doxecitine and Doxribtimine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.